oncotomskСибирский онкологический журналSiberian journal of oncology1814-48612312-3168Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences10.21294/1814-4861-2018-17-4-99-105oncotomsk-822Research ArticleОБЗОРЫREVIEWSХИТИНАЗОПОДОБНЫЕ БЕЛКИ КАК ПЕРСПЕКТИВНЫЕ МАРКЕРЫ ПРИ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЯХCHITINASE-LIKE PROTEINS AS PROMISING MARKERS IN CANCER PATIENTShttps://orcid.org/0000-0001-5758-7330ЛарионоваИ. В.LarionovaI. V.

Россия, 634050, г. Томск, пр. Ленина, 36

Россия, 634009, г. Томск, пер. Кооперативный, 5

младший научный сотрудник лаборатории трансляционной клеточной и молекулярной биомедицины, Национальный исследовательский Томский государственный университет; аспирант, Научно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наук 

SPIN-код: 6272-8422. Researcher ID (WOS): R-2391-2017. Author ID (Scopus): 57201182530

36, Lenina av., 634050-Tomsk, Russia

5, Kooperativny Street, Tomsk, Russia, 634050

Junior Researcher of Laboratory of Translational Cellular and Molecular Biomedicine, Tomsk State University; Postgraduate, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences 

Researcher ID (WOS): R-2391-2017. Author ID (Scopus): 57201182530

https://orcid.org/0000-0002-6236-6556СевастьяноваТ. Н.SevastyanovaT. N.

Россия, 634050, г. Томск, пр. Ленина, 36

Германия, 68167, Маннхайм, Theodor-Kutzer-Ufer, 1-3

научный сотрудник, Национальный исследовательский Томский государственный университет; аспирант, Институт Трансфузионной Медицины и Иммунологии, Медицинский факультет, Маннхайм, Университет Гейдельберга

36, Lenina av., 634050-Tomsk, Russia

1-3, Theodor-Kutzer-Ufer, 68167-Mannheim, Germany

Junior Researcher of Laboratory of Translational Cellular and Molecular Biomedicine, Tomsk State University; Postgraduate, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences 

Researcher ID (WOS): R-2391-2017. Author ID (Scopus): 57201182530

https://orcid.org/0000-0002-9347-7806РакинаА. А.RakinaA. A.

Россия, 634009, г. Томск, пр.Ленина, 32

инженер, Национальный исследовательский Томский политехнический университет

SPIN-код: 2569-1297. Researcher ID (WOS): O-6297-2018

 

30, Lenina av., Tomsk, Russia, 634050

Engineer, National Research Tomsk Polytechnic University 

Researcher ID (WOS): O-6297-2018.

https://orcid.org/0000-0003-1526-9013ЧердынцеваН. В.CherdyntsevaN. V.

Россия, 634050, г. Томск, пр. Ленина, 36

Россия, 634009, г. Томск, пер. Кооперативный, 5

доктор биологических наук, профессор, член-корреспондент РАН, заведующая лабораторией молекулярной онкологии и иммунологии, Научно-исследовательский  институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наук; ведущий научный сотрудник, Национальный исследовательский Томский государственный университет

SPIN-код: 5344-0990. Researcher ID (WOS): С-7943-2012. Author ID (Scopus): 6603911744

36, Lenina av., 634050-Tomsk, Russia

5, Kooperativny Street, Tomsk, Russia, 634050

DSс, Professor, Corresponding member of Russian Academy of Sciences, the Head of the Laboratory of Molecular oncology and immunology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences; senior researcher of Laboratory of translational cellular and molecular biomedicine, Tomsk State University 

Researcher ID (WOS): С-7943-2012. Author ID (Scopus): 6603911744

nvch@tnimc.ruhttps://orcid.org/0000-0003-0898-3075КжышковскаЮ. Г.KzhyshkowskaJu. G.

Россия, 634050, г. Томск, пр. Ленина, 36

Германия, 68167, Маннхайм, Theodor-Kutzer-Ufer, 1-3

Германия, 68167, Маннхайм, Friedrich-Ebert, 107

доктор биологических наук, профессор, заведующая лабораторией трансляционной клеточной и молекулярной биомедицины, Национальный исследовательский Томский государственный университет; заведующая отделом врожденного иммунитета и толерантности, Институт трансфузионной медицины и иммунологии, Медицинский факультет, Университет Гейдельберга 

SPIN-код: 2465-2280. Researcher ID (WOS): J-5835-2016. Author ID (Scopus): 6603091281

36, Lenina av., 634050-Tomsk, Russia

1-3, Theodor-Kutzer-Ufer, 68167-Mannheim, Germany

107, Friedrich-Ebert Str., 68167-Mannheim, Germany

DSс, Professor, the Head of the Laboratory of translational cellular and molecular biomedicine, Tomsk State University; Head of Department of Innate Immunity and Tolerance, Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, University of Heidelberg 

Researcher ID (WOS): J-5835-2016. Author ID (Scopus): 6603091281

Национальный исследовательский Томский государственный университет Научно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наукРоссияTomsk State University Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of SciencesRussian FederationНациональный исследовательский Томский государственный университет Институт трансфузионной медицины и иммунологии, Медицинский факультет, Маннхайм, Университет ГейдельбергаРоссияTomsk State University Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, University of HeidelbergRussian FederationНациональный исследовательский Томский политехнический университетРоссияNational Research Tomsk Polytechnic UniversityRussian FederationНациональный исследовательский Томский государственный университет Институт трансфузионной медицины и иммунологии, Медицинский факультет, Маннхайм, Университет Гейдельберга Служба крови Немецкого Красного Креста Баден-Вюртемберг-ГессенРоссияTomsk State University Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, University of Heidelberg German Red Cross Blood Service Baden-Württemberg-HessenRussian Federation20180409201817499105Copyright © Ларионова И.В., Севастьянова Т.Н., Ракина А.А., Чердынцева Н.В., Кжышковска Ю.Г., 20182018Ларионова И.В., Севастьянова Т.Н., Ракина А.А., Чердынцева Н.В., Кжышковска Ю.Г.Larionova I.V., Sevastyanova T.N., Rakina A.A., Cherdyntseva N.V., Kzhyshkowska J.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.siboncoj.ru/jour/article/view/822

В обзоре проанализированы данные о роли хитиназоподобных белков (CLP), принадлежащих к семейству  белков, содержащих Glyco_18 домен и не обладающих ферментативной активностью, при различных  злокачественных новообразованиях. У человека идентифицировано 3 таких белка: YKL-40 (CHI3L1), YKL-39  (CHI3L2) и стабилин-связывающий CLP (SI-CLP). Хитиназоподобные белки, продуцируемые различными типами  клеток, в том числе опухолевыми, проявляют активность как цитокины и ростовые факторы, а также  они вовлечены в процессы воспаления. Высокий уровень CLP определяется в циркулирующей крови при  воспалительных заболеваниях и разных локализациях злокачественных опухолей. Освещены данные о  ключевых функциях CLP в физиологических и патологических условиях. Проанализированы сведения о  вовлечении CLP в процессы инвазии, метастазирования, ангиогенеза, их связи с опухолевой прогрессией.  Представлены собственные результаты, подтверждающие перспективность разработки прогностических и  предсказательных маркеров на основе CLP при злокачественных новообразованиях.

In the present review we collected the main studies regarding the role of chitinase-like proteins (CLPs), belonging to the family of Glyco_18 domain-containing proteins, in different cancers. In  humans, 3 chitinaselike proteins have been identified: YKL-40 (CHI3L1), YKL-39 (CHI3L2) and  stabilin-1-interacting chitinase-like protein (SI-CLP). CLPs are produced by several types of cells  and combine the properties of cytokines and growth factors. The high levels of CLPs were  identified in the circulation of the patients with inflammatory diseases and various types of  tumors. We highlighted the main known functions of CLPs in normal and pathological conditions, their contribution to metastasis development, angiogenesis, invasion and other processes in  cancer, the correlation of the levels of CLPs with tumour progression. Our data also contribute to the understanding of question how CLP could be useful for cancer patient benefit.

хитиназоподобные белкиCLPYKL-30YKL-40SI-CLPзлокачественные новообразованияопухолевая прогрессияchitinase-like proteinsCLPYKL-30YKL-40SI-CLPcancertumor progressionReferencesKzhyshkowska J., Gratchev, A., Goerdt, S. Human chitinases and chitinase-like proteins as indicators for inflammation and cancer. Biomark Insights. 2007 May 3; 2: 128–46.Kzhyshkowska J., Gratchev, A., Goerdt, S. Human chitinases and chitinase-like proteins as indicators for inflammation and cancer. Biomark Insights. 2007 May 3; 2: 128–46.Shuhui L., Mok Y.K., Wong W.S. Role of mammalian chitinases in asthma. Int Arch Allergy Immunol. 2009; 149(4): 369–77. doi: 10.1159/000205583.Shuhui L., Mok Y.K., Wong W.S. Role of mammalian chitinases in asthma. Int Arch Allergy Immunol. 2009; 149(4): 369–77. doi: 10.1159/000205583.Donnelly L.E., Barnes, P.J. Acidic mammalian chitinase–a potential target for asthma therapy. Trends Pharmacol Sci. 2004 Oct; 25(10): 509–11. doi: 10.1016/j.tips.2004.08.002.Donnelly L.E., Barnes, P.J. Acidic mammalian chitinase–a potential target for asthma therapy. Trends Pharmacol Sci. 2004 Oct; 25(10): 509–11. doi: 10.1016/j.tips.2004.08.002.Zhu Z., Zheng T., Homer R.J., Kim Y.-K., Chen N.Y., Cohn L., Hamid Q., Elias J.A. Acidic mammalian chitinase in asthmatic Th2 inflammation and IL-13 pathway activation. Science. 2004 Jun 11; 304(5677): 1678–82. doi: 10.1126/science.1095336.Zhu Z., Zheng T., Homer R.J., Kim Y.-K., Chen N.Y., Cohn L., Hamid Q., Elias J.A. Acidic mammalian chitinase in asthmatic Th2 inflammation and IL-13 pathway activation. Science. 2004 Jun 11; 304(5677): 1678–82. doi: 10.1126/science.1095336.Boot R.G., Renkema G.H., Strijland A., van Zonneveld A.J., Aerts J.M. Cloning of a cDNA encoding chitotriosidase, a human chitinase produced by macrophages. J Biol Chem. 1995 Nov 3; 270(44): 26252–6.Boot R.G., Renkema G.H., Strijland A., van Zonneveld A.J., Aerts J.M. Cloning of a cDNA encoding chitotriosidase, a human chitinase produced by macrophages. J Biol Chem. 1995 Nov 3; 270(44): 26252–6.Boven L.A., van Meurs M., Boot R.G., Mehta A., Boon L., Aerts J.M., Laman J.D. Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol. 2004 Sep; 122(3): 359–69. doi: 10.1309/BG5V-A8JR-DQH1-M7HN.Boven L.A., van Meurs M., Boot R.G., Mehta A., Boon L., Aerts J.M., Laman J.D. Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol. 2004 Sep; 122(3): 359–69. doi: 10.1309/BG5V-A8JR-DQH1-M7HN.Hu B., Trinh K., Figueira W.F., Price P.A. Isolation and sequence of a novel human chondrocyte protein related to mammalian members of the chitinase protein family. J Biol Chem. 1996 Aug 9; 271(32): 19415–20.Hu B., Trinh K., Figueira W.F., Price P.A. Isolation and sequence of a novel human chondrocyte protein related to mammalian members of the chitinase protein family. J Biol Chem. 1996 Aug 9; 271(32): 19415–20.Jin H.M., Copeland N.G., Gilbert D.J., Jenkins N.A., Kirkpatrick R.B., Rosenberg M. Genetic characterization of the murine Ym1 gene and identification of a cluster of highly homologous genes. Genomics. 1998 Dec 1; 54(2): 316–22. doi: 10.1006/geno.1998.5593.Jin H.M., Copeland N.G., Gilbert D.J., Jenkins N.A., Kirkpatrick R.B., Rosenberg M. Genetic characterization of the murine Ym1 gene and identification of a cluster of highly homologous genes. Genomics. 1998 Dec 1; 54(2): 316–22. doi: 10.1006/geno.1998.5593.Kzhyshkowska J., Mamidi S., Gratchev A., Kremmer E., Schmuttermaier C., Krusell L., Haus G., Utikal J., Schledzewski K., Scholtze J., Goerdt S. Novel stabilin-1 interacting chitinase-like protein (SI-CLP) is up-regulated in alternatively activated macrophages and secreted via lysosomal pathway. Blood. 2006 Apr 15; 107(8): 3221– 8. doi: 10.1182/blood-2005-07-2843.Kzhyshkowska J., Mamidi S., Gratchev A., Kremmer E., Schmuttermaier C., Krusell L., Haus G., Utikal J., Schledzewski K., Scholtze J., Goerdt S. Novel stabilin-1 interacting chitinase-like protein (SI-CLP) is up-regulated in alternatively activated macrophages and secreted via lysosomal pathway. Blood. 2006 Apr 15; 107(8): 3221– 8. doi: 10.1182/blood-2005-07-2843.Kzhyshkowska J., Yin S., Liu T., Riabov V., Mitrofanova I. Role of chitinase-like proteins in cancer. Biol Chem. 2016 Mar; 397(3): 231–47. doi: 10.1515/hsz-2015-0269. doi: 10.1515/hsz-2015-0269.Kzhyshkowska J., Yin S., Liu T., Riabov V., Mitrofanova I. Role of chitinase-like proteins in cancer. Biol Chem. 2016 Mar; 397(3): 231–47. doi: 10.1515/hsz-2015-0269. doi: 10.1515/hsz-2015-0269.Ranok A., Wongsantichon J., Robinson R.C., Suginta W. Structural and thermodynamic insights into chitooligosaccharide binding to human cartilage chitinase 3-like protein 2 (CHI3L2 or YKL-39). J Biol Chem. 2015 Jan 30; 290(5): 2617–29. doi: 10.1074/jbc.M114.588905.Ranok A., Wongsantichon J., Robinson R.C., Suginta W. Structural and thermodynamic insights into chitooligosaccharide binding to human cartilage chitinase 3-like protein 2 (CHI3L2 or YKL-39). J Biol Chem. 2015 Jan 30; 290(5): 2617–29. doi: 10.1074/jbc.M114.588905.Schimpl M., Rush C.L., Betou M., Eggleston I.M., Recklies A.D., van Aalten D.M. Human YKL-39 is a pseudo-chitinase with retained chitooligosaccharide-binding properties. Biochem J. 2012 Aug 15; 446(1): 149–57. doi: 10.1042/BJ20120377.Schimpl M., Rush C.L., Betou M., Eggleston I.M., Recklies A.D., van Aalten D.M. Human YKL-39 is a pseudo-chitinase with retained chitooligosaccharide-binding properties. Biochem J. 2012 Aug 15; 446(1): 149–57. doi: 10.1042/BJ20120377.Bigg H.F., Wait R., Rowan A.D., Cawston T.E. The mammalian chitinase-like lectin, YKL-40, binds specifically to type I collagen and modulates the rate of type I collagen fibril formation. J Biol Chem. 2006 Jul 28; 281(30): 21082–95. doi: 10.1074/jbc.M601153200.Bigg H.F., Wait R., Rowan A.D., Cawston T.E. The mammalian chitinase-like lectin, YKL-40, binds specifically to type I collagen and modulates the rate of type I collagen fibril formation. J Biol Chem. 2006 Jul 28; 281(30): 21082–95. doi: 10.1074/jbc.M601153200.Fusetti F., Pijning T., Kalk K.H., Bos E., Dijkstra B.W. Crystal structure and carbohydrate-binding properties of the human cartilage glycoprotein-39. J Biol Chem. 2003 Sep 26; 278(39): 37753‑60. doi: 10.1074/jbc.M303137200.Fusetti F., Pijning T., Kalk K.H., Bos E., Dijkstra B.W. Crystal structure and carbohydrate-binding properties of the human cartilage glycoprotein-39. J Biol Chem. 2003 Sep 26; 278(39): 37753‑60. doi: 10.1074/jbc.M303137200.Renkema G.H., Boot R.G., Au F.L., Donker-Koopman W.E., Strijland A., Muijsers A.O., Hrebicek M., Aerts J.M. Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur J Biochem. 1998 Jan 15; 251(1‑2): 504–9.Renkema G.H., Boot R.G., Au F.L., Donker-Koopman W.E., Strijland A., Muijsers A.O., Hrebicek M., Aerts J.M. Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur J Biochem. 1998 Jan 15; 251(1‑2): 504–9.Nishikawa K.C., Millis A.J. gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Exp Cell Res. 2003 Jul 1; 287(1): 79–87.Nishikawa K.C., Millis A.J. gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Exp Cell Res. 2003 Jul 1; 287(1): 79–87.Meng G., Zhao Y., Bai X., Liu Y., Green T.J., Luo M., Zheng X. Structure of human stabilin-1 interacting chitinase-like protein (SI-CLP) reveals a saccharide-binding cleft with lower sugar-binding selectivity. J Biol Chem. 2010 Dec 17; 285(51): 39898–904. doi: 10.1074/jbc.M110.130781.Meng G., Zhao Y., Bai X., Liu Y., Green T.J., Luo M., Zheng X. Structure of human stabilin-1 interacting chitinase-like protein (SI-CLP) reveals a saccharide-binding cleft with lower sugar-binding selectivity. J Biol Chem. 2010 Dec 17; 285(51): 39898–904. doi: 10.1074/jbc.M110.130781.Chang N.C., Hung S.I., Hwa K.Y., Kato I., Chen J.E., Liu C.H., Chang A.C. A macrophage protein, Ym1, transiently expressed during inflammation is a novel mammalian lectin. J Biol Chem. 2001 May 18; 276(20): 17497–506. doi: 10.1074/jbc.M010417200.Chang N.C., Hung S.I., Hwa K.Y., Kato I., Chen J.E., Liu C.H., Chang A.C. A macrophage protein, Ym1, transiently expressed during inflammation is a novel mammalian lectin. J Biol Chem. 2001 May 18; 276(20): 17497–506. doi: 10.1074/jbc.M010417200.Sekine T., Masuko-Hongo K., Matsui T., Asahara H., Takigawa M., Nishioka K., Kato T. Recognition of YKL-39, a human cartilage related protein, as a target antigen in patients with rheumatoid arthritis. Ann Rheum Dis. 2001 Jan; 60(1): 49–54.Sekine T., Masuko-Hongo K., Matsui T., Asahara H., Takigawa M., Nishioka K., Kato T. Recognition of YKL-39, a human cartilage related protein, as a target antigen in patients with rheumatoid arthritis. Ann Rheum Dis. 2001 Jan; 60(1): 49–54.Shao R. Secreted glycoprotein YKL-40: A potential cancer biomarker and therapeutic target. Integr Cancer Sci Therap. 2018; 5(1): 1–1. doi: 10.15761/ICST.1000268.Shao R. Secreted glycoprotein YKL-40: A potential cancer biomarker and therapeutic target. Integr Cancer Sci Therap. 2018; 5(1): 1–1. doi: 10.15761/ICST.1000268.Johansen J.S. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull. 2006 May; 53(2): 172–209.Johansen J.S. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull. 2006 May; 53(2): 172–209.Rathcke C.N., Vestergaard H. YKL-40, a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis. Inflamm Res. 2006 Jun; 55(6): 221‑7. doi: 10.1007/s00011-006-0076-y.Rathcke C.N., Vestergaard H. YKL-40, a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis. Inflamm Res. 2006 Jun; 55(6): 221‑7. doi: 10.1007/s00011-006-0076-y.Johansen J.S., Jensen B.V., Roslind A., Nielsen D., Price P.A. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev. 2006 Feb; 15(2): 194–202. doi: 10.1158/1055-9965.EPI-05-0011.Johansen J.S., Jensen B.V., Roslind A., Nielsen D., Price P.A. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev. 2006 Feb; 15(2): 194–202. doi: 10.1158/1055-9965.EPI-05-0011.Suzuki T., Hashimoto S., Toyoda N., Nagai S., Yamazaki N., Dong H.Y., Sakai J., Yamashita T., Nukiwa T., Matsushima K. Comprehensive gene expression profile of LPS-stimulated human monocytes by SAGE. Blood 2000; 96: 2584–91.Suzuki T., Hashimoto S., Toyoda N., Nagai S., Yamazaki N., Dong H.Y., Sakai J., Yamashita T., Nukiwa T., Matsushima K. Comprehensive gene expression profile of LPS-stimulated human monocytes by SAGE. Blood 2000; 96: 2584–91.Liu T., Larionova I., Litviakov N., Riabov V., Zavyalova M., Tsyganov M., Buldakov M., Song B., Moganti K., Kazantseva P., Slonimskaya E., Kremmer E., Flatley A., Klüter H., Cherdyntseva N., Kzhyshkowska J. Tumor-associated macrophages in human breast cancer produce new monocyte attracting and pro-angiogenic factor YKL-39 indicative for increased metastasis after neoadjuvant chemotherapy. Oncoimmunology. 2018 Mar 13; 7(6): e1436922. doi: 10.1080/2162402X.2018.1436922Liu T., Larionova I., Litviakov N., Riabov V., Zavyalova M., Tsyganov M., Buldakov M., Song B., Moganti K., Kazantseva P., Slonimskaya E., Kremmer E., Flatley A., Klüter H., Cherdyntseva N., Kzhyshkowska J. Tumor-associated macrophages in human breast cancer produce new monocyte attracting and pro-angiogenic factor YKL-39 indicative for increased metastasis after neoadjuvant chemotherapy. Oncoimmunology. 2018 Mar 13; 7(6): e1436922. doi: 10.1080/2162402X.2018.1436922Shao R., Hamel K., Petersen L., Cao Q.J., Arenas R.B., Bigelow C., Bentley B., Yan W. YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene. 2009 Dec 17; 28(50): 4456–68. doi: 10.1038/onc.2009.292.Shao R., Hamel K., Petersen L., Cao Q.J., Arenas R.B., Bigelow C., Bentley B., Yan W. YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene. 2009 Dec 17; 28(50): 4456–68. doi: 10.1038/onc.2009.292.Francescone R.A., Scully S., Faibish M., Taylor S.L., Oh D., Moral L., Yan W., Bentley B., Shao R. Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma. J Biol Chem. 2011 Apr 29; 286(17): 15332–43. doi: 10.1074/jbc.M110.212514.Francescone R.A., Scully S., Faibish M., Taylor S.L., Oh D., Moral L., Yan W., Bentley B., Shao R. Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma. J Biol Chem. 2011 Apr 29; 286(17): 15332–43. doi: 10.1074/jbc.M110.212514.Faibish M., Francescone R., Bentley B., Yan W., Shao R. A YKL-40-neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers. Mol Cancer Ther. 2011; 10: 742–51. doi: 10.1158/1535-7163.MCT-10-0868.Faibish M., Francescone R., Bentley B., Yan W., Shao R. A YKL-40-neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers. Mol Cancer Ther. 2011; 10: 742–51. doi: 10.1158/1535-7163.MCT-10-0868.Salamon J., Hoffmann T., Elies E., Peldschus K., Johansen J.S., Lüers G., Schumacher U., Wicklein D. Antibody directed against human YKL-40 increases tumor volume in a human melanoma xenograft model in scid mice. PLoS One. 2014 Apr 21; 9(4): e95822. doi: 10.1371/journal.pone.0095822.Salamon J., Hoffmann T., Elies E., Peldschus K., Johansen J.S., Lüers G., Schumacher U., Wicklein D. Antibody directed against human YKL-40 increases tumor volume in a human melanoma xenograft model in scid mice. PLoS One. 2014 Apr 21; 9(4): e95822. doi: 10.1371/journal.pone.0095822.Wan G., Xiang L., Sun X., Wang X., Li H., Ge W., Cao F. Elevated YKL-40 expression is associated with a poor prognosis in breast cancer patients. Oncotarget. 2017 Jan 17; 8(3): 5382–5391. doi: 10.18632/oncotarget.14280.Wan G., Xiang L., Sun X., Wang X., Li H., Ge W., Cao F. Elevated YKL-40 expression is associated with a poor prognosis in breast cancer patients. Oncotarget. 2017 Jan 17; 8(3): 5382–5391. doi: 10.18632/oncotarget.14280.Saidi A., Javerzat S., Bellahcène A., De Vos J., Bello L., Castronovo V., Deprez M., Loiseau H., Bikfalvi A., Hagedorn M. Experimental antiangiogenesis causes upregulation of genes associated with poor survival in glioblastoma. Int J Cancer. 2008 May 15; 122(10): 2187‑98. doi: 10.1002/ijc.23313.Saidi A., Javerzat S., Bellahcène A., De Vos J., Bello L., Castronovo V., Deprez M., Loiseau H., Bikfalvi A., Hagedorn M. Experimental antiangiogenesis causes upregulation of genes associated with poor survival in glioblastoma. Int J Cancer. 2008 May 15; 122(10): 2187‑98. doi: 10.1002/ijc.23313.Nio J., Fujimoto W., Konno A., Kon Y., Owhashi M., Iwanaga T. Cellular expression of murine Ym1 and Ym2, chitinase family proteins, as revealed by in situ hybridization and immunohistochemistry. Histochem Cell Biol. 2004 Jun; 121(6): 473–82. doi: 10.1007/s00418-004-0654-4.Nio J., Fujimoto W., Konno A., Kon Y., Owhashi M., Iwanaga T. Cellular expression of murine Ym1 and Ym2, chitinase family proteins, as revealed by in situ hybridization and immunohistochemistry. Histochem Cell Biol. 2004 Jun; 121(6): 473–82. doi: 10.1007/s00418-004-0654-4.Kawada M., Seno H., Kanda K., Nakanishi Y., Akitake R., Komekado H., Kawada K., Sakai Y., Mizoguchi E., Chiba T. Chitinase 3-like 1 promotes macrophage recruitment and angiogenesis in colorectal cancer. Oncogene. 2012 Jun 28; 31(26): 3111–23. doi: 10.1038/onc.2011.498.Kawada M., Seno H., Kanda K., Nakanishi Y., Akitake R., Komekado H., Kawada K., Sakai Y., Mizoguchi E., Chiba T. Chitinase 3-like 1 promotes macrophage recruitment and angiogenesis in colorectal cancer. Oncogene. 2012 Jun 28; 31(26): 3111–23. doi: 10.1038/onc.2011.498.Tang H., Sun Y., Shi Z., Huang H., Fang Z., Chen J., Xiu Q., Li B. YKL-40 induces IL-8 expression from bronchial epithelium via MAPK (JNK and ERK) and NF-κB pathways, causing bronchial smooth muscle proliferation and migration. J Immunol. 2013 Jan 1; 190(1): 438–46. doi: 10.4049/jimmunol.1201827.Tang H., Sun Y., Shi Z., Huang H., Fang Z., Chen J., Xiu Q., Li B. YKL-40 induces IL-8 expression from bronchial epithelium via MAPK (JNK and ERK) and NF-κB pathways, causing bronchial smooth muscle proliferation and migration. J Immunol. 2013 Jan 1; 190(1): 438–46. doi: 10.4049/jimmunol.1201827.Jefri M., Huang Y.N., Huang W.C., Tai C.S., Chen W.L. YKL-40 regulated epithelial- mesenchymal transition and migration/invasion enhancement in non-small cell lung cancer. BMC Cancer. 2015 Aug 15; 15: 590. doi: 10.1186/s12885-015-1592-3.Jefri M., Huang Y.N., Huang W.C., Tai C.S., Chen W.L. YKL-40 regulated epithelial- mesenchymal transition and migration/invasion enhancement in non-small cell lung cancer. BMC Cancer. 2015 Aug 15; 15: 590. doi: 10.1186/s12885-015-1592-3.Schultz N.A., Johansen J.S. YKL-40-A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients? Cancers (Basel). 2010 Jul 12; 2(3): 1453‑91. doi: 10.3390/cancers2031453.Schultz N.A., Johansen J.S. YKL-40-A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients? Cancers (Basel). 2010 Jul 12; 2(3): 1453‑91. doi: 10.3390/cancers2031453.Shao R., Cao Q.J., Arenas R.B., Bigelow C., Bentley B., Yan W. Breast cancer expression of YKL-40 correlates with tumour grade, poor differentiation, and other cancer markers. Br J Cancer. 2011 Oct 11; 105(8): 1203–9. doi: 10.1038/bjc.2011.347.Shao R., Cao Q.J., Arenas R.B., Bigelow C., Bentley B., Yan W. Breast cancer expression of YKL-40 correlates with tumour grade, poor differentiation, and other cancer markers. Br J Cancer. 2011 Oct 11; 105(8): 1203–9. doi: 10.1038/bjc.2011.347.Litviakov N., Tsyganov M., Larionova I., Ibragimova M., Deryusheva I., Kazantseva P., Slonimskaya E., Frolova I., Choinzonov E., Cherdyntseva N., Kzhyshkowska J. Expression of M2 macrophage markers YKL-39 and CCL18 in breast cancer is associated with the effect of neoadjuvant chemotherapy. Cancer Chemother Pharmacol. 2018 Jul; 82(1): 99–109. doi: 10.1007/s00280-018-3594-8.Litviakov N., Tsyganov M., Larionova I., Ibragimova M., Deryusheva I., Kazantseva P., Slonimskaya E., Frolova I., Choinzonov E., Cherdyntseva N., Kzhyshkowska J. Expression of M2 macrophage markers YKL-39 and CCL18 in breast cancer is associated with the effect of neoadjuvant chemotherapy. Cancer Chemother Pharmacol. 2018 Jul; 82(1): 99–109. doi: 10.1007/s00280-018-3594-8.Kavsan V.M., Baklaushev V.P., Balynska O.V., Iershov A.V., Areshkov P.O., Yusubalieva G.M., Grinenko N.P., Victorov I.V., Rymar V.I., Sanson M., Chekhonin V.P. Gene Encoding Chitinase 3-Like 1 Protein (CHI3L1) is a Putative Oncogene. Int J Biomed Sci. 2011 Sep; 7(3): 230–7.Kavsan V.M., Baklaushev V.P., Balynska O.V., Iershov A.V., Areshkov P.O., Yusubalieva G.M., Grinenko N.P., Victorov I.V., Rymar V.I., Sanson M., Chekhonin V.P. Gene Encoding Chitinase 3-Like 1 Protein (CHI3L1) is a Putative Oncogene. Int J Biomed Sci. 2011 Sep; 7(3): 230–7.Itik V., Kemik O., Kemik A., Dulger A.C., Sümer A., Soyoral Y.U., Begenik H., Purisa S., Kotan C. Serum YKL-40 Levels in Patients with Gastric Cancer. Biomark Cancer. 2011 May 4; 3: 25–30. doi: 10.4137/BIC.S7154.Itik V., Kemik O., Kemik A., Dulger A.C., Sümer A., Soyoral Y.U., Begenik H., Purisa S., Kotan C. Serum YKL-40 Levels in Patients with Gastric Cancer. Biomark Cancer. 2011 May 4; 3: 25–30. doi: 10.4137/BIC.S7154.Dupont J., Tanwar M.K., Thaler H.T., Fleisher M., Kauff N., Hensley M.L., Sabbatini P., Anderson S., Aghajanian C., Holland E.C., Spriggs D.R. Early detection and prognosis of ovarian cancer using serum YKL-40. J Clin Oncol 2004; 22: 3330–9. doi: 10.1200/JCO.2004.09.112.Dupont J., Tanwar M.K., Thaler H.T., Fleisher M., Kauff N., Hensley M.L., Sabbatini P., Anderson S., Aghajanian C., Holland E.C., Spriggs D.R. Early detection and prognosis of ovarian cancer using serum YKL-40. J Clin Oncol 2004; 22: 3330–9. doi: 10.1200/JCO.2004.09.112.Yasar O., Akcay T., Obek C., Turegun F.A. Diagnostic potential of YKL-40 in bladder cancer. Urol Oncol. 2016 Jun; 34(6): 257.e19‑24. doi: 10.1016/j.urolonc.2016.02.003.Yasar O., Akcay T., Obek C., Turegun F.A. Diagnostic potential of YKL-40 in bladder cancer. Urol Oncol. 2016 Jun; 34(6): 257.e19‑24. doi: 10.1016/j.urolonc.2016.02.003.Bi J., Lau S.H., Lv Z.L., Xie D., Li W., Lai Y.R., Zhong J.M., Wu H.Q., Su Q., He Y.L., Zhan W.H., Wen J.M., Guan X.Y. Overexpression of YKL-40 is an independent prognostic marker in gastric cancer. Hum Pathol. 2009 Dec; 40(12): 1790–7. doi: 10.1016/j.humpath.2009.07.005.Bi J., Lau S.H., Lv Z.L., Xie D., Li W., Lai Y.R., Zhong J.M., Wu H.Q., Su Q., He Y.L., Zhan W.H., Wen J.M., Guan X.Y. Overexpression of YKL-40 is an independent prognostic marker in gastric cancer. Hum Pathol. 2009 Dec; 40(12): 1790–7. doi: 10.1016/j.humpath.2009.07.005.Johansen J.S., Drivsholm L., Price P.A., Christensen I.J. High serum YKL-40 level in patients with small cell lung cancer is related to early death. Lung Cancer. 2004; 46: 333–340. doi: 10.1016/j.lungcan.2004.05.010.Johansen J.S., Drivsholm L., Price P.A., Christensen I.J. High serum YKL-40 level in patients with small cell lung cancer is related to early death. Lung Cancer. 2004; 46: 333–340. doi: 10.1016/j.lungcan.2004.05.010.Cintin C., Johansen J.S., Christensen I.J., Price P.A., Sørensen S., Nielsen H.J. High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival. Cancer. 2002; 95: 267–274. doi: 10.1002/cncr.10644.Cintin C., Johansen J.S., Christensen I.J., Price P.A., Sørensen S., Nielsen H.J. High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival. Cancer. 2002; 95: 267–274. doi: 10.1002/cncr.10644.Johansen J.S., Bojesen S.E., Mylin A.K., Frikke-Schmidt R., Price P.A., Nordestgaard B.G. Elevated plasma YKL-40 predicts increased risk of gastrointestinal cancer and decreased survival after any cancer diagnosis in the general population. J Clin Oncol. 2009 Feb 1; 27(4): 572–8. doi: 10.1200/JCO.2008.18.8367.Johansen J.S., Bojesen S.E., Mylin A.K., Frikke-Schmidt R., Price P.A., Nordestgaard B.G. Elevated plasma YKL-40 predicts increased risk of gastrointestinal cancer and decreased survival after any cancer diagnosis in the general population. J Clin Oncol. 2009 Feb 1; 27(4): 572–8. doi: 10.1200/JCO.2008.18.8367.Chang S.T., Zahn J.M., Horecka J., Kunz P.L., Ford J.M., Fisher G.A., Le Q.T., Chang D.T., Ji H., Koong A.C. Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis. J Transl Med. 2009 Dec 11; 7: 105. doi: 10.1186/1479-5876-7-105.Chang S.T., Zahn J.M., Horecka J., Kunz P.L., Ford J.M., Fisher G.A., Le Q.T., Chang D.T., Ji H., Koong A.C. Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis. J Transl Med. 2009 Dec 11; 7: 105. doi: 10.1186/1479-5876-7-105.

The authors declare that there are no conflicts of interest present.